Pronounced State-Level Disparities in Prescription of Cannabinoids to Medicaid Patients.

ABSTRACT:

Introduction

Dronabinol is approved in the USA for chemotherapy-induced nausea as well as vomiting and HIV-induced anorexia, while cannabidiol is primarily approved for childhood epileptic disorders Lennox-Gastaut and Dravet syndrome. The use pattern for these prescription cannabinoids in the USA is unknown. This study examined Medicaid claims for two FDA-approved prescription cannabinoids, dronabinol and cannabidiol, approved in 1985 and 2018, respectively, from 2016-2020 to better understand the pharmacoepidemiologic trends and distribution of these drugs in US Medicaid amidst the increasing use of non-pharmaceutical formulations of cannabis.

Methods

The longitudinal study analyzed Medicaid prescription claims that were calculated by extracting the prescriptions on a state

SUBMITTER: Liu EY 

PROVIDER: S-EPMC10315157 | biostudies-literature | 2023 Jan-Dec

REPOSITORIES: biostudies-literature